- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01767584
Bioequivalence Study of Cephalexin Tablets 1g
Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations Containing 1 g of Cephalexin (GlaxoSmithKline México, S.A. de C.V. vs. Keflex® 1g, Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers.
The objective of this study was to confirm if two formulations of cephalexin tablets are bioequivalent.
Test product was Ceporex® (1 g Cephalexin; GlaxoSmithKline) and reference product Keflex® (1 g Cephalexin; Eli Lilly). The single dosage was one tablet.
The study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fasting conditions.
The population was composed of 26 healthy volunteers, both genders, adults between 18-40 years.
The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Free will participation according to Mexican regulation, Helsinki Declaration, and Good Clinical Practice.
Healthy, between 18 and 40 years. Body Mass Index between 19 and 27 In good health by complete medical history and laboratory tests. Blood pressure 130-90/ 90-60 mm Hg; heart rate 55-100 beat per minute, respiratory rate 14-20 movements per minute.
Laboratory tests +/- 10% of normal interval (blood cytology, blood chemistry 27 elements, Hepatitis B and C antigens, HIV, urinalysis, anti-doping, pregnancy, electrocardiogram) -
Exclusion Criteria:
Alteration of vital signs Not complying with inclusion criteria History of cardiovascular, kidney, hepatic, muscular, metabolic, gastrointestinal (including constipation), neurologic, endocrine, hematopoietic (any kind of anemia), asthma, mental or organic disease. Those suffering from muscular trauma 21 days before the beginning of the study.
Requirement of any kind of medication during the course of the study, except study medication.
History of dyspepsia, gastritis, esophagitis, duodenal or gastric ulcer. Exposure to medications known as inducers or inhibitors of hepatic enzymes or administration of potentially toxic medication in the 30 days before the study beginning.
Administration of any medication in the 14 days or 5 half-lives (whatever longer) previous to the beginning of the study.
Hospitalization for any cause in the seven months before the beginning of the study.
Administration of investigational drugs in the 60 days before the study. Allergy to any antibiotic or non-steroidal anti-inflammatory analgesic. Alcohol ingestion or intake of beverages containing xanthines (coffee, tea, cocoa, chocolate, mate, cola drinks) or ingestion of charcoal grilled food or grapefruit or orange juice in the 72 hours before the hospitalization or tobacco smoking in the 72 hours before the beginning of the study.
Blood donation or loss => 450 ml in the 60 days before the beginning of the study.
History of drug or alcohol abuse. Positive pregnancy test. Special diet requirement, for instance vegetarian diet. Inability to understand nature, aims, and possible consequences of the study. Evidence of non-cooperative attitude during the study.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A (reference)/ B (test)
initial administration of reference and cross-over to test
|
Reference product
Other Names:
Test product
Other Names:
|
Experimental: B (test)/ A (reference)
initial administration of test and cross-over to reference
|
Reference product
Other Names:
Test product
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Plasma Concentration (CMAX) of cephalexin
Time Frame: 0.0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 postdosage
|
Pharmacokinetics
|
0.0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 postdosage
|
Area under the plasma concentration versus time curve (AUC) of cephalexin
Time Frame: 0.0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 postdosage
|
Pharmacokinetics
|
0.0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 postdosage
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 116999
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections, Respiratory Tract
-
Vakzine Projekt Management GmbHFGK Clinical Research GmbHUnknownInfection, Respiratory TractGermany
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory TractGermany
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory TractAustralia
-
GlaxoSmithKlineCompletedInfections, Respiratory Tract
-
GlaxoSmithKlineCompletedInfections, Respiratory Syncytial VirusUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory Syncytial VirusCanada
Clinical Trials on Cephalexin 1g tablets
-
BayerCorporación Bonima S.A. de C.V.CompletedAnti-Infective AgentsMexico
-
Ottawa Hospital Research InstituteThe Ottawa Hospital Academic Medical Association; Network of Canadian Emergency...Recruiting
-
Institut National de la Santé Et de la Recherche...Completed
-
BayerCorporación Bonima S.A. de C.V.CompletedAnti-Infective AgentsMexico
-
BayerCorporación Bonima S.A. de C.V.CompletedAnti-Infective AgentsMexico
-
Pierre Fabre MedicamentCompleted
-
Orpha LabsUnknownGlycogen Storage Disease, Type 14Turkey
-
University of California, San FranciscoCompletedSoft Tissue InfectionsUnited States
-
Brett A FaineUniversity of California, Los AngelesNot yet recruitingPyelonephritis Acute
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteCompletedBipolar DepressionIreland